[A26-75] Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Addendum to Commission A26-12
Last updated 06.08.2026
Project no.:
A26-75
Commission:
Commission awarded on 23.06.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Indication:
Adults with WHO functional class IV pulmonary arterial hypertension
Result of dossier assessment:
After addendum now: hint of a non-quantifiable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-75_V1.1
| Project no. | Title | Status |
|---|---|---|
| A26-12 | Sotatercept (pulmonary arterial hypertension, WHO functional class IV) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision